Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study provides a comprehensive analysis of anabolic-androgenic steroids, reporting that their use enhances muscle mass but is associated with significant health issues including cardiac muscle hypertrophy, liver disease, and changes in gender characteristics, emphasizing the need for patient awareness of these risks.

Apremilast may help treat hair loss in alopecia areata.

This study examined the effectiveness of FT-Raman spectroscopy for detecting polymorphism in Lamivudine and Finasteride, highlighting its advantages over other methods due to its capability to provide sharp, well-resolved spectral bands and reduced sampling issues.

Mycophenolic acid may help hair grow by activating pathways important for hair growth.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

In this study, carbon dots derived from metformin and dopamine (MD‐CDs) effectively promoted healing in bacterial-infected wounds by inhibiting infection, expediting inflammation-to-healing transition, enhancing cell proliferation and migration, and fostering collagen deposition and hair follicle regeneration.

This study found that the ACE gene I/D polymorphism may serve as a genetic susceptibility indicator for androgenetic alopecia in an Egyptian patient group.

This study reports that the newly optimized AR antagonist 39 demonstrated effective hair growth and safety in a mouse model of androgenetic alopecia, showing comparable efficacy to pyrilutamide with faster response and favorable pharmacokinetics, due to innovative structural design and dual metabolic inactivation strategy.

This report describes a case of acute localised exanthematous pustulosis in a 19-year-old boy after using amoxicillin-clavulanic acid, with new dermoscopic features identified.

This report documents a 14-year-old Chinese boy with mitochondrial encephalopathy, lactic acidosis, stroke-like episodes, and a de novo A3243G mitochondrial DNA mutation, highlighting the condition's multisystem involvement without ragged red fibers in muscle biopsy.

This study suggests that male sex and androgenic steroid use increase the risk of atrial arrhythmias in individuals with arrhythmogenic right ventricular cardiomyopathy, especially those with desmosomal gene mutations.

This review discusses available treatments for androgenetic alopecia in men, like finasteride and 5% minoxidil, and notes that hair growth results are unpredictable and often driven by industry-sponsored studies.

In this study, the addition of a topical gel containing growth-factor mimicking oligopeptides and other ingredients showed improved efficacy in subjects with androgenic alopecia using minoxidil or finasteride compared to drug treatment alone.

In this study, selective overexpression of androgen receptors in muscle cells increased lean muscle mass and reduced fat mass in transgenic rodents, suggesting a potential target for drug development.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

In this study, testosterone was found to increase the risk of arrhythmias in a rat heart model, while finasteride reduced this arrhythmogenic effect.

This study found that platelet-rich plasma may be an effective adjuvant treatment for androgenetic alopecia, especially when combined with antiandrogenetic medications and topical minoxidil, though factors like patient age and family history could influence outcomes.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This study suggests that the AGA risk haplotype in Europeans was driven to high frequency by positive selection, likely associated with a variant in the EDA2R gene.

This study observed that amelanotic melanocytes from human hair follicles appeared morphologically immature, suggesting they might not transfer melanosomes into keratinocytes.

Blocking adenosine A2B receptor may prevent or treat hearing loss.

This study indicates that individuals exposed to PPD mount varying immune responses, with either tolerance, subclinical inflammation, or allergy, suggesting no true non-responders to PPD.

This study elucidated the multi-component and multi-target mechanisms by which TR and Am may provide therapeutic benefits for treating androgenetic alopecia.

This study found that a novel dietary supplement, AGA-P, when combined with minoxidil and finasteride, significantly improved the clinical efficacy of these drugs for treating mild-to-severe androgenic alopecia compared to drug treatment alone over six months.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.